Estimo, Wilbert P.
HRN: 24-70-14 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/22/2024
CO-AMOXICLAV 625MG (TAB)
03/22/2024
03/29/2024
PO
625mg
Q8H
Multiple Abrasions, Face
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes